Relmada Therapeutics Files 8-K on Shareholder Votes and Financials
Ticker: RLMD · Form: 8-K · Filed: May 30, 2024 · CIK: 1553643
| Field | Detail |
|---|---|
| Company | Relmada Therapeutics, Inc. (RLMD) |
| Form Type | 8-K |
| Filed Date | May 30, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, corporate-governance, financials
TL;DR
Relmada Therapeutics filed an 8-K on May 24th, covering shareholder votes and financials.
AI Summary
Relmada Therapeutics, Inc. filed an 8-K on May 30, 2024, reporting on matters submitted to a vote of security holders and financial statements as of May 24, 2024. The company, formerly known as Camp Nine, Inc., is incorporated in Nevada and headquartered in Coral Gables, Florida.
Why It Matters
This filing provides updates on corporate governance and financial status, which are crucial for investors to assess the company's operational health and decision-making processes.
Risk Assessment
Risk Level: low — This is a routine 8-K filing reporting on standard corporate events and financial statements, not indicating any immediate material adverse changes.
Key Players & Entities
- RELMADA THERAPEUTICS, INC. (company) — Registrant
- CAMP NINE, INC. (company) — Former Company Name
- May 24, 2024 (date) — Date of earliest event reported
- May 30, 2024 (date) — Date of Report
- Nevada (jurisdiction) — State of Incorporation
- Coral Gables, FL (location) — Principal Executive Offices
FAQ
What specific matters were submitted to a vote of security holders?
The filing indicates that 'Submission of Matters to a Vote of Security Holders' is an item reported, but the specific details of these matters are not provided in the excerpt.
What is the exact date of the financial statements mentioned in the filing?
The filing states the 'Date as of Change' for the financial statements is May 24, 2024.
When was Relmada Therapeutics, Inc. formerly known as Camp Nine, Inc.?
The date of the name change from Camp Nine, Inc. to Relmada Therapeutics, Inc. was July 6, 2012.
What is the principal executive office address of Relmada Therapeutics, Inc.?
The principal executive offices are located at 2222 Ponce de Leon Blvd., 3rd Floor, Coral Gables, FL 33134.
What is the SIC code for Relmada Therapeutics, Inc.?
The Standard Industrial Classification (SIC) code for Relmada Therapeutics, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 733 words · 3 min read · ~2 pages · Grade level 11.1 · Accepted 2024-05-30 16:05:35
Key Financial Figures
- $0.001 — nge on which registered Common stock, $0.001 par value per share RLMD The Nasdaq
Filing Documents
- ea0207126-8k_relmada.htm (8-K) — 37KB
- 0001213900-24-047968.txt ( ) — 210KB
- rlmd-20240524.xsd (EX-101.SCH) — 3KB
- rlmd-20240524_lab.xml (EX-101.LAB) — 34KB
- rlmd-20240524_pre.xml (EX-101.PRE) — 22KB
- ea0207126-8k_relmada_htm.xml (XML) — 4KB
07. Submission of Matters to
Item 5.07. Submission of Matters to a Vote of Security Holders. On May 24, 2024, Relmada Therapeutics, Inc. (the "Company") held its 2024 Annual Meeting of Stockholders (the "Annual Meeting"). Of the 30,174,202 shares of the Company's common stock outstanding and eligible to vote at the Annual Meeting, 21,986,343 shares, or approximately 72.9 % of the eligible common stock, were present either in person or by proxy and voted. The final results of the matters voted on at the Annual Meeting are provided below. Proposal 1: Election of Directors. Stockholders elected the following nominees as directors to hold office until the 2027 Annual Meeting (i.e. as a Class III Director) and until his successor is elected and qualified. Nominee For Withheld Broker Non-Votes John Glasspool (Class III, 36 month term) 7,693,573 9,981,548 4,311,222 Paul Kelly (Class III, 36 month term) 11,799,277 5,875,844 4,311,222 The continuing Class I Directors are Eric Schmidt and Fabiana Fedeli. The continuing Class II Directors are Charles J. Casamento and Sergio Traversa. Proposal 2: Ratification of Appointment of Independent Auditors. Stockholders approved the ratification of the appointment of Marcum LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024. For Against Abstentions Broker Non-Votes 19,984,165 1,966,620 35,558 - Proposal 3: Approval of an Amendment to the 2021 Plan. Stockholders did not approve the proposed amendment to the Company's 2021 Equity Incentive Plan, as amended (the "2021 Plan"), to increase the number of shares of the Company's common stock available for issuance pursuant to awards under the 2021 Plan by 4,500,000 to an aggregate of 12,400,000 (including awards previously granted). The 2021 Plan is described in more detail in the Company's 2024 Proxy Statement, which was filed with the Securities and Exchange Commission on April 9, 2024. For Against Abs
Executive Compensation
Executive Compensation. Stockholders did not approve, on an advisory basis, the compensation paid to the Company's named executive officers, as disclosed in the Company's Proxy Statement for its 2024 Annual Meeting of Stockholders. For Against Abstentions Broker Non-Votes 7,529,377 10,119,590 26,154 4,311,222
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: May 30, 2024 RELMADA THERAPEUTICS, INC. By: /s/ Sergio Traversa Name: Sergio Traversa Title: Chief Executive Officer